Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS) (Q28252010)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS)	scientific article

Statements

scholarly article

0 references

Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS) (English)

0 references

myocardial infarction

1 reference

based on heuristic

inferred from title

circulatory system

1 reference

based on heuristic

inferred from title

author name string

Jian-Jun Li

1

0 references

Zong-Liang Lu

2

0 references

Wen-Rong Kou

3

0 references

Zuo Chen

4

0 references

Yang-Feng Wu

5

0 references

Xue-Hai Yu

6

0 references

Yu-Cheng Zhao

7

0 references

language of work or name

0 references

publication date

August 2009

0 references

The Journal of Clinical Pharmacology

0 references

49

0 references

8

0 references

947-56

0 references

Sudden cardiac death: epidemiology, mechanisms, and therapy

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337509

21 January 2018

Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337509

21 January 2018

Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction. A 12-year follow-up of the Finnmark Study

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337509

21 January 2018

Major causes of death among men and women in China

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337509

21 January 2018

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337509

21 January 2018

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337509

21 January 2018

Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337509

21 January 2018

Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease.

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337509

21 January 2018

Effects of xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337509

21 January 2018

Xuezhikang, an extract of cholestin, decreases plasma inflammatory markers and endothelin-1, improve exercise-induced ischemia and subjective feelings in patients with cardiac syndrome X.

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337509

21 January 2018

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337509

21 January 2018

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337509

21 January 2018

Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337509

21 January 2018

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337509

21 January 2018

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337509

21 January 2018

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337509

21 January 2018

Total Serum Cholesterol Levels and Mortality Risk as a Function of Age

1 reference

https://api.crossref.org/works/10.1177%2F0091270009337509

21 January 2018

Identifiers

10.1177/0091270009337509

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28252010&oldid=1239788588"